CPHL Pharmaceuticals: Major
Health Technology
Mkt Cap
17.4B
P/E (TTM)
16.08
EPS
3.90
ROE
13.28%
Div Yield
4.58%
About
Citi Pharma Ltd. engages in the manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. Its products portfolio includes paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic Acid. The company was founded on October 8, 2012 and is headquartered in Lahore, Pakistan.
Financial Highlights
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Revenue | 13.15B | 12.41B | 12.40B | 9.78B | 5.80B | |
| Gross Profit | 1.92B | 1.50B | 1.44B | 1.30B | 742.86M | |
| Net Income | 892.04M | 833.46M | 657.98M | 653.69M | 351.77M | |
| EPS | 3.90 | 3.65 | 2.88 | 2.88 | 4.22 | |
| ROE | 10.81% | 15.15% | 13.05% | 14.40% | 13.15% | |
| ROA | 5.98% | 7.78% | 7.27% | 8.94% | 7.84% | |
| Gross Margin | 14.57% | 12.06% | 11.63% | 13.25% | 12.82% | |
| Net Margin | 6.78% | 6.72% | 5.31% | 6.68% | 6.07% | |
| Current Ratio | 1.30 | 1.36 | 1.48 | 1.86 | 2.45 | |
| DPS | 3.50 | 3.25 | 2.50 | 0.00 | 1.36 | |
| Free Cash Flow | -470.77M | 769.40M | -1.28B | -923.43M | 469.08M |